Zhijie Wang clinical trials
Zhijie Wang is the lead sponsor of 3 current clinical trials in our China register. None of its ClinicalTrials.gov trials is recruiting at the moment. All registered phases are Phase 2. The drugs named most often in its trials are Carboplatin. The most-studied condition is SMARCA4-Deficient Tumor.
ClinicalTrials.gov trials by status
Trials by phase
Clinical trials sponsored by Zhijie Wang
3 on ClinicalTrials.gov| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
A Phase II Study of QL1706 With Anti-angiogenesis Therapy and Chemotherapy in Extensive-stage Small Cell Lung Cancer.
NCT07083375 · ClinicalTrials.gov ↗ · Extensive Small Cell Lung Cancer
Drug: Carboplatin |
Phase 2 | Not yet open | 2025-08 | China |
|
A Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
NCT07200947 · ClinicalTrials.gov ↗ · SMARCA4-Deficient Tumor, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
|
Phase 2 | Not yet open | 2025-12 | China |
|
A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer.
NCT07307443 · ClinicalTrials.gov ↗ · SMARCA4-Deficient Tumor, Locally Advanced or Metastatic Lung Cancer
|
Phase 2 | Not yet open | 2026-02 | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs in Zhijie Wang trials
1 compoundDrugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
Conditions in Zhijie Wang trials
4 conditionsBy trial register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 3 | 0 |
A trial with sites in more than one country appears in each of those registers.
Questions about Zhijie Wang trials
How many clinical trials does Zhijie Wang sponsor?
Zhijie Wang is the lead sponsor of 3 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Zhijie Wang trials recruiting?
Not at the moment. None of its 3 ClinicalTrials.gov trials is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Which drugs is Zhijie Wang testing?
Its current trials name 1 drug or biological as interventions. The most frequent are Carboplatin (1). The number in brackets is how many of its trials name each drug.
Where does this information come from?
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
How this page is built
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
- EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.